|
M.V. Leonova
Bempedoic acid – a new drug in lipid-lowering therapy
|
№14 / 2023
|
|
E.V. Biryukova, M.V. Shinkin, I.A. Morozovа
Modern practice of lipid-lowering pharmacotherapy: the choice of the optimal fixed combination
|
№3 / 2023
|
|
O.A. Polyakova, Yu.M. Tkachenko, O.D. Ostroumova
Relationship between non-alcoholic fatty liver disease and cardiovascular disease: focus on the use of ursodeoxycholic acid
|
№1-2 / 2023
|
|
A.F. Verbovoy, N.I. Verbovaya, L.A. Sharonova
Hypothyroidism is an untimely diagnosed disease
|
№11-12 / 2022
|
|
M.S. Novikova, O.M. Koteshkova, M.B. Antsiferov
Efficacy and safety of ertugliflozin: results of the VERTIS CV sub-study in patients receiving a stable dose of insulin
|
№4 / 2022
|
|
D.I. Trukhan, D.S. Ivanova
Drug safety in real clinical practice: focus on protective therapy
|
№3 / 2022
|
|
M.B. Antsiferov (1), O.M. Koteshkova (1), M.S. Novikova (1), N.A. Demidov (2)
Possibilities of dapagliflozin in cardio-reno-metabolic protection in patients with and without type 2 diabetes mellitus
|
№12 / 2021
|
|
A.F. Verbovoy, Yu.A. Dolgikh
Insulin resistance – a common enemy for endocrinologists and cardiologists
|
№12 / 2021
|
|
N.A. Karoli, A.P. Rebrov
Beta-blockers in patients with chronic obstructive pulmonary disease: for whom, when, how?
|
№5 / 2020
|
|
V.Ya. Dzerve
ENERGY METABOLISM CORRECTOR MILDRONATE®: INTERRELATION OF MECHANISMS OF ACTION AND THERAPEUTIC EFFECTS
|
№15 / 2017
|
|
M.A. Ayrapetyan, I.G. Gordeev, N.A. Volov
GENDER FEATURES OF ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION
|
№9 / 2017
|
|
V.N. Shishkova
PROBLEMS OF COMORBID PATIENT AND POLYPRAGMASY IN NEUROLOGY
|
№9 / 2017
|
Русский
